Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2023-10-24 Investor Presentation
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
关于召开2023年第三季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the upcoming 2023 third quarter earnings explanation meeting (业绩说明会) scheduled for October 31, 2023. It provides details about the meeting time, location, format (online interaction), participants, and how investors can submit questions. The document does not contain actual financial statements or detailed financial analysis but rather informs investors about the event where such information will be discussed. This fits the description of an Investor Presentation (IP) as it is a detailed presentation for investors focusing on financials, strategy, and market position, specifically an earnings explanation meeting. The document length is short (1445 characters), but it is not merely announcing the release of a report; it is announcing the meeting to discuss the quarterly results. Therefore, the best classification is Investor Presentation (IP).
2023-10-24 Chinese
关于募集资金专用账户部分资金被冻结的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the freezing of a portion of the company's convertible bond fundraising special account funds due to a legal dispute. It details the amount frozen, the reason for the freeze, the impact on the company, and the company's response. There are no financial statements or comprehensive financial data presented. The document is a regulatory announcement about a specific event affecting the company's fundraising account, not a full financial report or earnings release. It fits best under Regulatory Filings (RNS) as it is a compliance disclosure about a legal and financial matter affecting the company.
2023-10-18 Chinese
安信证券股份有限公司关于深圳微芯生物科技股份有限公司募集资金专用账户部分资金被冻结的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed investigation opinion from a sponsoring securities company regarding the freezing of part of the funds in a special account for raised funds related to a convertible bond issuance. It discusses the frozen bank account, the reason for freezing (a contract dispute and court case), the impact on the company, and the sponsor's opinion on the matter. It is not a financial report, earnings release, or management discussion. It is a regulatory disclosure related to a legal and financial status update about fundraising funds but does not contain financial statements or earnings data. It is not a report publication announcement since it contains substantive content and analysis. The document fits best under Regulatory Filings (RNS) as it is a compliance disclosure about a material event affecting the company’s fundraising funds and legal status, but not a formal audit, annual, or interim report.
2023-10-18 Chinese
关于可转债转股结果暨股份变动的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the convertible bond conversion results and related share capital changes for Shenzhen Microchip Biotechnology Co., Ltd. It details the amount of convertible bonds converted into shares during a specific quarter and cumulatively, as well as the remaining unconverted bonds. It also provides background on the bond issuance and conversion terms. The document is relatively short (1719 characters) and focuses on reporting the conversion results and share capital changes rather than providing a full financial report or detailed analysis. This type of document fits the category of Capital/Financing Update (CAP), as it updates on the company's financing activities related to convertible bonds and share capital changes.
2023-10-08 Chinese
关于“微芯转债”预计触发转股价格向下修正条件的提示性公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding the potential triggering of a downward adjustment condition for the conversion price of its convertible bonds. It details the terms of the convertible bond issuance, the conditions under which the conversion price may be adjusted downward, the procedures for such adjustment, and a risk warning to investors. The document is regulatory in nature, providing a compliance update about convertible bond terms and potential price adjustments, but it does not contain financial statements, earnings data, or detailed financial analysis. It is not an annual or interim report, earnings release, or management discussion. It is also not a report publication announcement since it contains substantive information rather than just announcing a report's release. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-08-28 Chinese
安信证券股份有限公司关于深圳微芯生物科技股份有限公司2023年半年度持续督导跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2023年半年度持续督导跟踪报告" which translates to "2023 Semi-Annual Continuous Supervision Tracking Report" by the sponsor (安信证券) for the company 深圳微芯生物科技股份有限公司. It contains detailed information about the company's operations, financial data for the first half of 2023, risk factors, R&D progress, use of raised funds, shareholding details, and compliance with regulatory requirements. The document is comprehensive and covers a half-year period with substantive financial data and analysis, including income, profit, cash flow, and R&D expenses. It is not a full annual report but a detailed interim report covering six months. It is not a mere announcement or certification but a full report with financial and operational details. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-25 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.